New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. - Wikidata - awgldk - TriplyDB

New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

http://www.wikidata.org/entity/Q37996449

about

Managing anticoagulation for atrial fibrillation: current issues and future strategies Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.How to report results of prothrombin and activated partial thromboplastin times.Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey.Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants.Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test.The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats.Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.

P2860

Q26991728-BF1A3F9C-5B5C-48D1-B666-3496F951573F Q35069871-F3120162-260D-415C-8DB2-A8ECE5E6ED72 Q38583376-CA8A3226-F42F-476D-881F-D2BE0B4442E3 Q38674332-F74C18D2-9177-4C18-8CF5-C25A3C3B1C1C Q43106166-486C0F49-4128-4F74-AA0C-C69B63A43BA4 Q43585970-AA77CCD4-9060-4F20-B39C-2D68F3CA3A8A Q48104079-E093A4E3-88A3-454B-B1D0-A85AE096E369 Q48299604-4585F5F8-8101-487A-AADA-97D3DBB6EFF7

P2860

New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

http://www.wikidata.org/entity/Q37996449

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@en

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@nl

type

label

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@en

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@nl

prefLabel

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@en

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@nl

P1433

Q37996449-DFF22FBC-6F0B-4F44-A091-C3C3ACA71CB0

P1476

Q37996449-971DCA40-1B25-4554-AC3E-7546E19B2C09

P2093

Q37996449-9520B62F-078D-4F41-9C2C-011F1C3E6893

Q37996449-994FD168-6E5D-4455-9664-B9C2E893B005

P2860

Q37996449-020715E5-9914-4C05-9A7A-CE0C4F9F4E4D

Q37996449-12CD7DDA-D45A-467D-A0CD-C15158252866

Q37996449-1555AE54-6A29-4132-91CD-75C8AE503078

Q37996449-1EE7AE7B-BCD9-43F8-A6FC-B7FA440E76E1

Q37996449-206914B8-AC70-4902-A844-AC4045338269

Q37996449-3142EB9A-8756-4C63-9EAC-34307D4D28E1

Q37996449-34A97956-617D-4F19-B767-1B4016C1CFBD

Q37996449-3733C5D0-81E5-4E6A-9914-E636ABC79DB5

Q37996449-3785E4E6-9B98-4A4A-B4E0-D1E20A3B9EFB

Q37996449-38FF65BA-7602-4DBE-8419-765699B25306

P304

Q37996449-7540261B-2C4F-40A4-9425-851DB783D169

P31

Q37996449-4A4C8B10-4D40-4D7D-8D05-899160A578F5

P356

Q37996449-735C4B37-092D-4D0E-A03E-61BF764B5C61

P407

Q37996449-1F7A1B0D-201B-460E-8B3F-FA10EAE370F3

P433

Q37996449-5C9260B1-A800-44A4-BDED-FB239FED26F5

P478

Q37996449-1DE8106C-A2DD-4EEC-8244-260659DF8BD9

P577

Q37996449-C40A2B7E-FD42-4CAA-B2AC-256FC51D5C61

P5875

Q37996449-2F79691A-8984-4FD8-B61B-7516CE9299EA

P698

Q37996449-DCAF0E90-E84D-41BF-B65E-5A88C1069C1D

P921

Q37996449-12B88F92-E96E-49EA-A80D-7CC0846D6139

Q37996449-25FC66E7-F2AE-4B8B-84CD-A19AA724073D

Q37996449-DD5F8A39-506E-4FA7-9615-20F52A59F3FF

P356

J.1365-2796.2012.02541.X

P1433

Journal of Internal Medicine

P1476

New anticoagulant drugs for tr ...... ention in atrial fibrillation.

@en

P2093

A Tripodi

http://www.w3.org/2001/XMLSchema#string

G Palareti

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Oral rivaroxaban for symptomatic venous thromboembolism

Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography.

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Apixaban in patients with atrial fibrillation.

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

P304

554-565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2796.2012.02541.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

271

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221972052

http://www.w3.org/2001/XMLSchema#string

P698

22443239

http://www.w3.org/2001/XMLSchema#string

P921

venous thromboembolism

anticoagulation

atrial fibrillation